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ABSTRACT The ability of myosin to generate motile forces is based on elastic distortion of a structural element of the actomy-
osin complex (cross-bridge) that allows strain to develop before ﬁlament sliding. Addressing the question, which part of the acto-
myosin complex experiences main elastic distortion, we suggested previously that the converter domain might be the most
compliant region of the myosin head domain. Here we test this proposal by studying functional effects of naturally occurring
missense mutations in the b-myosin heavy chain, 723Arg / Gly (R723G) and 736Ile / Thr (I736T), in comparison to
719Arg/ Trp (R719W). All three mutations are associated with hypertrophic cardiomyopathy and are located in the converter
region of the myosin head domain. We determined several mechanical parameters of single skinned slow ﬁbers isolated from
Musculus soleus biopsies of hypertrophic cardiomyopathy patients and healthy controls. Major ﬁndings of this study for mutation
R723G were i), a >40% increase in ﬁber stiffness in rigor with a 2.9-fold increase in stiffness per myosin head (S*rigor R723G ¼
0.84 pN/nm S*rigor WT ¼ 0.29 pN/nm); and ii), a signiﬁcant increase in force per head (F*10C, 1.99 pN vs. 1.49 pN ¼ 1.3-fold
increase; F*20C, 2.56 pN vs. 1.92 pN¼ 1.3-fold increase) as well as stiffness per head during isometric steady-state contraction
(S*active10C, 0.52 pN/nm vs. 0.28 pN/nm¼ 1.9-fold increase). Similar changes were found for mutation R719W (2.6-fold increase
in S*rigor; 1.8-fold increase in F*10C, 1.6-fold in F*20C; twofold increase in S*active10C). Changes in active cross-bridge cycling
kinetics could not account for the increase in force and active stiffness. For the above estimates the previously determined fraction
of mutatedmyosin in the biopsies was taken into account. Data for wild-typemyosin of slow soleusmuscle ﬁbers support previous
ﬁndings that for the slowmyosin isoformS* andF* are signiﬁcantly lower than for fastmyosin e.g., of rabbit psoasmuscle. The data
indicate that twomutations, R723G and R719W, are associated with an increase in resistance to elastic distortion of the individual
mutated myosin heads whereas mutation I736T has essentially no effect. The data strongly support the notion that major elastic
distortion occurs within the converter itself. Apparently, the compliance depends on speciﬁc residues, e.g., R719 and R723,
presumably located at strategic positions near the long a-helix of the light chain binding domain. Because amino acids 719
and 723 are nonconserved residues, cross-bridge stiffness may well be speciﬁcally tuned for different myosins.INTRODUCTION
Force generation and shortening of skeletal muscle depends
on structural changes of the myosin head domain that are
coupled to ATP-hydrolysis. The ability of myosin to drive
sliding of the actin filaments during isotonic shortening as
well as its ability to generate isometric force is thought to
depend on elastic distortion of a structural element of the
actomyosin complex (cross-bridge). Such elastic distortion
that was proposed in very early models of muscle contrac-
tion, allows strain to develop within the motor before the
cargo is actually moved (1,2). Relief of this strain then drives
filament sliding. It is, however, still unclear which part of the
actomyosin complex represents the element that experiences
the main elastic distortion whereas other parts may act more
like rigid bodies. One possibility is that the light chain
binding domain of the myosin head, i.e., the long a-helix
with the two associated light chains undergoes bending (3–5).
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0006-3495/09/08/0806/19 $2.00Alternatively, the acto-myosin interface (6), subfragment
2 (7) or the junction between catalytic domain and light chain
binding domain (4) have been considered as regions of main
elastic distortion during force generation. Fiber diffraction
studies do not have the resolution to answer this question.
Cryo-electron microscopy and protein crystallography can
also not resolve this question because this requires study of
elastically distorted cross-bridges in the process of generating
isometric force in muscle.
Studying functional effects of missense mutations in the
head domain of the cardiac myosin isoform (b-MHC) that
occur naturally in hypertrophic cardiomyopathy (HCM)
enabled us to address this question. Familial HCM is
a genetically determined cardiac disorder that in 50–60%
of families is associated with and most likely caused by
mutations in genes encoding sarcomeric proteins (8,9).
We found previously that a mutation that is located in the
converter region of the myosin head domain (R719W)
was associated with a significant increase in resistance to
elastic distortion (stiffness) of muscle fibers from an
HCM-patient carrying this mutation (10). We could show
doi: 10.1016/j.bpj.2009.05.023
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of the mutated myosin heads suggesting that the converter
region became stiffer. This indicates that the converter
region is one of the main elastically distorted elements of
the myosin head because only stiffening of a compliant
region will cause an increase in resistance to elastic distor-
tion of the whole cross-bridge.
We now extended our functional studies toward other
mutations also located in the converter domain, mutation
R723G and I736T, to test our hypothesis that the converter
is a key element of elastic distortion within the myosin head
domain. Furthermore, characterization of different mutations
in the converter regionwill also provide insight into structural
elements and interactions of amino acids within the converter
that are essential for the compliance of this region of the
myosin head. Finally, studies on HCM mutations in muscle
fibers from HCM patients allow us to not only address the
question of cross-bridge compliance but also to identify
primary functional changes that may trigger the development
of the cardiac disease in these patients.
Single fibers from soleus muscle of HCM patients and
control individuals containing the slow myosin isoform
(b/slow-MHC) were used for these studies. The use of slow
skeletal muscle fibers (type I fibers) for studies ofHCM-muta-
tions is possible because in humans b-MHC in slow-twitch
muscle is the product of the same gene on chromosome 14
that is expressed in the ventricle (11). This was confirmed
by studies of several different point mutations in b-MHC
that revealed the presence of themutated b-MHC in the sarco-
meres of the patient’s slow-twitch skeletal muscle (12–14).
Incorporation of myosin carrying an HCM mutation in the
head domain was shown previously not to cause alterations
in the structure and assembly of the thick filaments in the
contractile apparatus (10,15).
To examine whether the R723G and I736T mutations also
affect the resistance of the myosin head against elastic distor-
tion, i.e., the stiffness of the myosin head domain, as we had
found previously for the R719W mutation, we first deter-
mined the stiffness of skinned fibers with the R723G and
I736T mutations in the absence of nucleotide (rigor).
Because in rigor all cross-bridges are thought to be attached
to actin because of their very high actin affinity (16–18),
possible changes in fiber stiffness (S) could not be caused
by different fractions of cross-bridges attached to actin,
i.e., fiber stiffness in rigor should quite directly reflect
changes in stiffness of the individual cross-bridge (S*).
If fiber stiffness in rigor is changed by a mutation we
expect a corresponding change in fiber stiffness measured
during isometric steady-state contraction, unless cross-
bridge cycling kinetics are also modified by the mutation.
This is because in a model in which cross-bridges essentially
fall into two groups of states, weak binding, nonforce gener-
ating states and strong binding, force generating states,
stiffness of the myosin heads attached to actin in the half-
sarcomere (S) under isometric conditions depends on (19)Here n is the total number of turning-over myosin heads that
can bind to actin within a half-sarcomere (depending e.g., on
sarcomere length, i.e., filament overlap) and that presumably
equals the number of myosin heads that can attach under
rigor conditions. S* is the stiffness of an individual myosin
head or cross-bridge. fapp and gapp are parameters of cross-
bridge cycling kinetics: fapp is the apparent rate constant
for the transition of cross-bridges from the nonforce-gener-
ating weak binding into the force generating strong binding
states of the ATPase cycle, the transition that is associated
with Pi-release. gapp is the apparent rate constant of the return
to the nonforce generating states on ADP release and binding
of a new ATP-molecule. Return to weak binding states via
binding of inorganic phosphate to force generating cross-
bridges is not considered here as no inorganic phosphate is
added to the solutions. For effects of myofilament compli-
ance on observed fiber stiffness see Discussion. Changes in
fiber stiffness under isometric conditions, however, could
also result from changes in quick tension recovery (2) or in
actin binding kinetics of force-generating cross-bridges (20).
Thus, we measured fiber stiffness by imposing stretches/
releases of different speeds on the fibers.
If stiffness of an individual cross-bridge is changed by
a mutation, we also expect a corresponding change in active
force generation (F), unless i), the extent of elastic distortion
of a cross-bridge during force generation; and/or ii), again
cross-bridge turnover kinetics are also changed by the muta-
tions. This is because isometric force (F) is determined by (19)
F ¼ n  F  fapp=

fapp þ gapp

; (2a)
where
F ¼ S  y0: (2b)
In these equations, n, fapp, and gapp are defined as in Eq. 1.F* is
themean force generated by each individualmyosin head in the
force generating states and y0* is the mean elastic distortion of
an individual myosin head during isometric force generation.
Toprobe forpossiblechanges iny0*associatedwithamutation,
we measured the y0-value of control fibers and fibers
with mutant myosin by imposing very fast ramp shaped
releases onto isometrically contracting muscle fibers (T-plots
(20,21)). In these measurements y0 is the minimum distance
of filament sliding, i.e., the minimum release required to drop
isometric force to zero (22,23). y0 measures the extent of struc-
tural change within the cross-bridge, e.g., redocking of the
motor domain on actin and/or rotation of the lever arm, which
not only results in elastic distortion of the force generating
cross-bridge, y0*, but also in elastic extension of the myofila-
ments. Therefore, when quantifying effects of mutations on
cross-bridge stiffness (S*) and on y0*, we need to consider
contributions of myofilament compliance to observed fiber
stiffness S and observed y0 of the fibers (see Discussion).
S ¼ n  S  fapp=

fapp þ gapp

: (1)Biophysical Journal 97(3) 806–824
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affected by the mutations we measured the rate constant of
force redevelopment after a short period of unloaded isotonic
shortening (kredev), the isometric fiber ATPase activity, and
the maximum shortening velocity (vmax). Isometric fiber
ATPase activity and kredev allow us to characterize effects
of the mutations on cross-bridge turnover kinetics under
isometric conditions. The rate constant of force redevelop-
ment back to the isometric steady state in response to a period
of unloaded shortening (kredev (19)) is determined by
kredev ¼ fapp þ gapp: (3)
Again return of force generating cross-bridges to weak bind-
ing states via binding of inorganic phosphate is not consid-
ered. The ATP-turnover of a muscle fiber depends on
ATPase ¼ n  b  fapp  gapp=

fapp þ gapp

; (4)
where n, fapp, and gapp are defined as in Eq. 1, and b is the
number of half-sarcomeres within a given fiber. vmax is deter-
mined by cross-bridge cycling kinetics during unloaded
shortening of the sarcomeres. vmax is particularly sensitive
to changes in g2app, the rate constant for return of cross-
bridges to weak binding states, i.e., detachment, under
unloaded isotonic shortening conditions (1). g2app during
sarcomere shortening at negligible loads is coupled to fast
ADP-release (24), followed by ATP-induced dissociation
of the myosin head from actin (25,26).
Altogether, measurements of fiber stiffness in rigor and
during isometric contraction, as well as measurements of
isometric force and cross-bridge cycling kinetics along with
y0 during isometric contraction allow us to detect changes
in S* andF* and to distinguish effects ofmutations on cycling
kinetics. To quantify effects of a mutation on F* and S* from
these measurements, the abundance of the mutated myosin in
the muscle tissue from the patients has to be taken into
account that was found to be different for different point
mutations in the myosin head domain (13,14). A central
element to perform all these different measurements was to
provide a sufficiently large number of fibers in a standardized
state of preservation over a long period of time. This was
achieved by the specific freezing and storage procedure that
we had developed previously (27) and that was applied to
the biopsies immediately after excision of the tissue from
the patients or the control individuals.
We found that mutation R723G, which is located very
close to residue R719W in the core of the converter
(28,29), was associated with a >40% increase in fiber stiff-
ness in rigor, as well as a significant increase in force and
stiffness during isometric steady-state contraction. These
are qualitatively the same changes as found with mutation
R719W. In contrast, mutation I736T, which according to
different crystal structures of the myosin head domain
(28,29) is further away from the long a-helix and near the
surface of the converter domain did not significantly affectBiophysical Journal 97(3) 806–824any of the measured parameters, just a small but not signifi-
cant increase in rigor stiffness could be observed. Altogether
the data support our earlier proposal that elastic distortion
occurs within or near the converter domain itself, presumably
close to the start of the long a-helix of the light chain binding
domain. Sequence comparison shows that residues equivalent
to R719 and R723 are not conserved among different class II
myosins. Thus, our findings that mutations R719 and R723
can quite significantly change cross-bridge stiffness imply
that stiffness of the myosin head domain may well be quite
specifically adjusted for different functions. An account of
this work was published previously (30).
METHODS
Patients and biopsies
Muscle tissue of the Musculus soleus was obtained from five HCM patients
with three different b-MHC point mutations. All patients presented with
typical signs of HCM, including myocardial hypertrophy and abnormalities
in the electrocardiogram. The affected families showed an autosomal domi-
nant inheritance of the disease. Biopsies with mutation R719W were ob-
tained from the patient AI III-2 of the British family AI, published by
Anan et al. (31), including clinical data. Soleus biopsies were also taken
from two members, II-2 and II-5, of the HCM family 26 from Barcelona
who carry the b-MHC mutation R723G (called H27 and H28 thereafter)
published with clinical data by Enjuto et al. (32). Further, biopsies with
the I736T b-MHC mutation were obtained from the two HCM patients II-
4 and II-7 of the Caucasian family A from Kyrgyzstan (numbered H19
and H20) published by Perrot et al. (33).
Biopsies of the M. soleus of 10 different healthy individuals served as
controls. The control individuals were patients undergoing plastic surgery
and volunteers without any known impairment of cardiac or skeletal muscle
function. Controls also included two Kyrgyz individuals (caucasian origin).
Informed consent was obtained according to approved Ethics Committee
protocols of all involved centers. The investigation conforms with the prin-
ciples outlined in the Declaration of Helsinki. Excision of the biopsies, prep-
aration of small fiber bundles, permeabilization and long term storage of
fiber bundles was described in detail previously (10,27,34,35). Briefly, M.
soleus biopsies of ~10 mm  10 mm  15 mm were excised under local
anesthesia and immediately carefully dissected into small muscle fiber
bundles. After permeabilization in skinning solution with 0.5% Triton
X-100 (Roche Diagnostics, Mannheim, Germany), the fiber bundles were
equilibrated with skinning solutions containing increasing sucrose concentra-
tions (up to 2.0 M), rapidly frozen in liquid propane and stored in liquid
nitrogen, as described previously (27). Special care was taken to keep the
muscle tissue, the dissected bundles before and after freezing, and the isolated
fibers during all procedures at low temperature (2–5C). Skinning solution
contained six different protease inhibitors, 2 mM dithiothreitol, 10 mM gluta-
thione, and 5 mM 2,3-butanedione monoxime (details described in Ko¨hler
et al. (10) and Kraft et al. (34)). Biopsies from patients and from control indi-
viduals were treated in the same way during each step of the procedures. For
the experiments, small bundles of soleus muscle fibers were thawed in
skinning solution containing 2.0 M sucrose and equilibrated with skinning
solution of decreasing sucrose concentrations (27). Individual muscle fibers
were finally dissected from the bundles in skinning solution without sucrose
and used within the following 4 days. Data were obtained by alternating
frequently between experiments on mutated fibers and control fibers.
Solutions
All chemicals, except where noted, were obtained from Sigma-Aldrich
(Munich, Germany). Solutions were adjusted to pH 7.0 at the respective
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are shown. Skinning solutions with and without sucrose were prepared as
described earlier (34). Fiber stiffness during isometric steady-state contrac-
tion of fibers with mutation R719W and control fibers was determined earlier
in a separate set of experiments (see Table 2; (10)) with preactivating and
activating solutions containing 10 mM imidazole, 2 mM MgCl2, 2 mM
MgATP, 2 mM dithiothreitol, 10 mM caffeine, 10 mM sodium creatine
phosphate, 200 U/mL creatine phosphokinase (units defined according to
Sigma-Aldrich), and 3 mM EGTA or 3 mM Ca-EGTA, respectively. To
determine isometric fiber ATPase activity, isometric force and kredev, as
well as unloaded shortening velocity (vmax; Table 1) of all mutations and
of a corresponding group of control fibers, the following preactivating and
activating solutions were used: 10 mM imidazole, 2 mMa MgCl2, 3 mM
EGTA or 3 mM CaEGTA, respectively, 5 mM MgATP, 10 mM caffeine,
0.25 mM Ap5A, 5 mM NaN3, 50 U/mL lactate dehydrogenase, 250 U/mL
pyruvate kinase, 2 mM phosphoenolpyruvate, and ~0.2 mM NADH. Phos-
phoenolpyruvate and pyruvate kinase served not only as ATP-backup
system but also to determine fiber ATPase activity. Rephosphorylation of
ADP was coupled to the reduction of pyruvate to lactate by oxidation of
NADH to NADþ. The resulting change in absorbance was measured at
360 nm in a flow-through cuvette that was part of a temperature controlled
system in which solutions were circulated between a small trough for the
muscle fiber and the 5 mL flow-through cuvette. Total circulating volume
was 160 mL. These solutions were also used to measure fiber stiffness during
isometric steady-state contraction of control fibers and fibers with mutations
R723G and I736T, respectively (Table 1). Activating solutions withdifferent calcium-concentrations (from pCa 4.5 to pCa 6.6) for measure-
ments of isometric force and fiber stiffness in T-plots at different force levels
to determine y0 and filament compliance per half-sarcomere of control fibers
(cf. Fig. 5) were obtained by mixing relaxing solution (containing 3 mM
EGTA) and activating solution (containing 3 mM CaEGTA) in different
proportions. Ionic strength of all preactivating and activating solutions
was adjusted to 170 mM using potassium propionate.
To quickly remove MgATP when transferring the fibers from relaxing
conditions into rigor, fibers were put in ‘‘quick rinse’’ solution containing
10 mM imidazole, 2.5 mM EGTA, 7.5 mM EDTA, and 135 mM potassium
propionate for ~10 min. Subsequently, for measurements of fiber stiffness in
rigor, fibers were transferred into rigor-solution containing 10 mM imid-
azole, 2.5 mM EGTA, 2.5 mM EDTA, and 150 mM potassium propionate.
Mechanical experiments
Single fibers were isolated and mounted into the experimental setup as
described previously (34,36). Sarcomere length, which was monitored by
laser light diffraction, was adjusted to 2.4 mm for all fibers. Structural integ-
rity of the fibers was monitored with an inverted microscope at all stages of
the experiments. For precise values of force and stiffness per cross-sectional
area of mutant and control fibers, the diameter of the fibers was not only
determined with an inverted microscope from the bottom, but also through
another microscope from the side. Accordingly, pairs of corresponding
diameters were determined for each fiber at three spots along the length of
the fiber. From these values the average cross-sectional areas of the fibersTABLE 1 Maximum isometric force generation (Fmax) and parameters sensitive to cross-bridge cycling kinetics as well as stiffness
and y0-values of soleus muscle ﬁbers with myosin mutations and control ﬁbers measured in rigor and during isometric contraction
Mut R719W
norm.
Mut R723G norm. Mut I736T norm.
Controls norm.
Controls abs. values
Units for abs. valuesH27 H28 H19 H20 20C 10C
Fmax 1.43*
5 0.02
(14)
1.19*
5 0.01
(7)
1.22*
5 0.01
(14)
0.97
5 0.02
(7)
1.01
5 0.01
(20)
1.00
5 0.01
(45)
140.86
5 1.25
(45)
108.94
5 5.31
(36)
kN/m2 or kPa
kredev 1.00
5 0.05
(14)
1.11
5 0.04
(7)
1.09
5 0.06
(14)
0.91
5 0.04
(7)
0.97
5 0.03
(20)
1.00
5 0.04
(45)
2.69
5 0.06
(45)
0.27
5 0.02
(36)
s1
Fiber-ATPase 1.21*
5 0.02
(14)
0.97
5 0.04
(6)
0.98
5 0.02
(12)
0.97
5 0.05
(6)
1.03
5 0.03
(11)
1.00
5 0.03
(21)
0.95x
5 0.02
(21)
n.d.
ATP
S1 s
vmax 1.10
5 0.11
(6)
1.07
5 0.04
(8)
1.17*
5 0.04
(9)
0.95
5 0.04
(11)
1.00
5 0.03
(10)
1.00
5 0.03
(7)
3246.00
5 86.79
(7)
329.90
5 8.61
(10)
(nm/HS)s1
Fiber stiffness
in rigor at 5Cy
see Table 2 1.43*
5 0.21
(5)
1.59*
5 0.15
(6)
1.09
5 0.09
(7)
1.15
5 0.14
(10)
1.00
5 0.15
(6)
n.d. 17.7
5 2.7
(6)
kN  HS
m2  nm or kPa  HS/nm
Active fiber
stiffnessy
see Table 2 1.32*
5 0.10
(10)
1.43*
5 0.19
(6)
0.90
5 0.04
(7)
0.97
5 0.08
(11)
1.00
5 0.13
(9)
n.d. 13.2
5 1.7
(9)
kN  HS
m2  nm or kPa  HS/nm
abs. values abs. values
y0 (nm/HS)
z at 10C see Table 2 7.70
5 0.74
(9)
n.d. n.d. 7.76
5 0.44
(7)
n.d. 8.53
5 0.42
(6)
abs., absolute; HS, half-sarcomere; n.d., not determined; norm., normalized.
Isometric force at 10C of fibers with mutation R723G (H27) and I736T (H20) was 1.235 0.05 (n ¼ 9) times and 0.915 0.08 (n ¼ 11) times the force of
control fibers, respectively. Values in parentheses indicate number of fibers studied, data are mean values5 SE. All values are normalized to control fibers that
were measured in the same time period. All normalized values of Fmax, kredev, fiber-ATPase, and vmax shown here were measured at 20
C, rigor stiffness was
measured at 5C, active stiffness and y0 were determined at 10C.
*Significant changes compared to controls.
yFiber stiffness in rigor and isometric contraction measured at fastest speed of length change (~3–5 103 (nm/half-sarcomere)s1 for rigor and 2–5 103 (nm/
half-sarcomere)s1 for active stiffness).
zy0 and active stiffness of the control fibers were measured on a different set of fibers with Fmax ¼ 112.955 0.11 kPa.
xATPase activity was calculated based on ADP generated, fiber volume and an S1-content of 154 pmol S1/mL fiber volume (50).Biophysical Journal 97(3) 806–824
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with a subset of fibers showed that cross-sectional areas obtained with this
method are not significantly different from cross-sectional areas of the
same fibers under the same conditions determined from optical z-sections
recorded with a confocal microscope integrated into our mechanical set-up
(data not shown). For recording z-sections by confocal microscopy, fibers
were labeled with rhodamine-phalloidin in relaxing solution.
Measurements of isometric force (Fmax), kredev, and isometric fiber
ATPase were carried out according to methods described in detail previously
(cf. Figs. 6 A and 7 A; (34,37,38)). Unloaded shortening velocity (vmax) was
determined using the slack test protocol (cf. Fig. 8A; (39,40)). Details of vmax
measurements have been reported earlier (38). Fmax, kredev, and vmax were
measured at 10C and 20C. The effects of the mutations on isometric force
were essentially the same at 10C and at 20C, normalized data shown here
(Table 1) were recorded at 20C. Resistance to elastic distortion, i.e., fiber
stiffness, was measured with ramp-shaped stretches or releases of different
speeds applied to one end of the fibers (41). The length change was recorded
as change in sarcomere length. Sarcomere length was recorded using laser
light diffraction with the previously described averaging over different inci-
dent angles of the laser beam (u-averaging; see Brenner (41)). Velocity of
length change could be varied from 2 (nm/half-sarcomere)s1 to 5  103
(nm/half-sarcomere)s1 to obtain stiffness-speed relations. Fiber stiffness
in rigor was determined by applying ramp-shaped stretches to the fibers in
rigor solution. Previous experiments showed that rigor stiffness is essentially
the same at low (5C) and high temperature (20C; T. Kraft, unpublished
observation). Thus, we measured fiber stiffness in rigor at 5C. Active fiber
stiffness was measured by imposing ramp-shaped releases on fibers during
isometric steady-state contraction at 10C (see also Fig. 4, T-plots; (21)).
In both cases, chord stiffness was used as a measure of apparent fiber stiff-
ness. Chord stiffness was defined as DF/2 nm where DF is the change in
force when change in sarcomere length has reached 2 nm/half-sarcomere.
To ensure that only fibers with the slow b-MHC-isoform were included in
the analysis of functional properties, the fiber type had to be ascertained.
This was done in two ways. First by measuring kredev at maximum calcium
activation (pCa 4.5) and 10C at the beginning of each experiment. Second,
at the end of the experiments fibers were transferred into SDS-buffer and
frozen for later electrophoretic analysis (42). Combined measurements of
kredev and subsequent fiber type analysis by SDS-PAGE (10,35) showed
that all fibers identified as slow fibers (Type I) based on kredev contained
solely b-MHC, whereas fibers identified as fast soleus muscle fibers con-
tained a fast myosin isoform.
Data analysis
Values given in the text are mean5 SE, unless stated otherwise. Statistically
significant difference between means was established based on Student’s
t-test. A probability of <0.05 was considered statistically significant (p %
0.05). Statistical analysis, curve fitting to determine vmax from slack test
data, as well as curve fitting of fiber stiffness data (see Fig. 2) were done
with the software Origin (Microcal Software, Northampton, MA).
RESULTS
Effects of the mutations on ﬁber stiffness in rigor
Under rigor conditions essentially all cross-bridges are
attached to actin (16–18). Thus, recording of fiber stiffness
in rigor is the most straightforward test to find out whether
the mutations R723G and I736T affect cross-bridge stiffness
(S*), as found previously for mutation R719W. Fig. 1 A
shows stiffness recorded under rigor conditions, i.e., under
nucleotide free conditions, of fibers isolated from M. soleus
of two patients with mutation R723G and two patients withBiophysical Journal 97(3) 806–824mutation I736T. For comparison, stiffness in rigor of fibers
with mutation R719W obtained earlier in a different set of
experiments is also shown. Because in rigor dissociation of
attached myosin heads is very slow, fiber stiffness in rigor
is independent of the speed of stretch over a wide range of
speeds (43). Therefore, rigor stiffness was not recorded
over the whole available range of speeds of stretch. Instead,
in Fig. 1 A and also in Table 1 and Table 2 rigor stiffness
recorded at a speed of stretch of ~3–5  103 (nm/half-
sarcomere)s1 is shown. For mutation R719W a significant
FIGURE 1 Effects of myosin head domain mutations R719W, R723G,
and I736T on fiber stiffness. (A) Stiffness of soleus muscle fibers in the
absence of nucleotide (rigor) recorded at highest available speed of stretch
(~3–5  103 (nm/HS)s1). HS, half-sarcomere. T ¼ 5C; n ¼ 5–10 fibers.
(B) Fiber stiffness recorded during isometric contraction at highest available
speed of length change (~2–4 103 (nm/HS)s1); T¼ 10C to ensure struc-
tural integrity of fibers and stability of striation pattern throughout experi-
ments; n¼ 6–14 fibers. Mean values5 SE, normalized to rigor (A) or active
stiffness (B) of control fibers, respectively. *Statistically significant
difference compared to controls. Fiber stiffness for mutation R719W was
determined previously in a separate set of experiments, therefore the corre-
sponding control data are shown here in addition. For absolute values see
Table 1 and Table 2.
Cross-Bridge Compliance in Converter 811TABLE 2 Fiber stiffness in rigor and during isometric contraction as well as y0-values of ﬁbers with mutation R719W and controls
Mut R719W norm.
Controls for R719W
Units for abs. valuesnorm. abs. values
Fiber stiffness in rigory at 5C 1.45*5 0.13 (6) 1.005 0.19 (7) 12.95 2.6 (7) kN  HS
m2  nm or kPa  HS/nm
Active fiber stiffnessy at 10C 1.48*5 0.15 (9) 1.005 0.11 (14) 10.45 1.1 (14) kN  HS
m2  nm or kPa  HS/nmabs. values
y0 (nm/HS)
z at 10C 7.665 0.99 (9) 7.095 0.57 (14)
abs., absolute; HS, half-sarcomere; norm., normalized.
Values in parentheses indicate number of fibers studied, data are mean values5 SE. All values are normalized to control fibers that were measured in the same
time period.
*Significant changes compared to controls.
yData for mutation R719W and parallel controls were obtained in previous experiments with differently composed solutions (see also (10)), yielding values for
the controls somewhat different than shown in Table 1. For the control fibers shown here Fmax ¼ 72.65 4.05 kPa (n ¼ 19) at 10C and 130.495 6.72 kPa
(n¼ 19) at 20C, isometric force of fibers with mutation R719W was at 10C 1.595 0.07 times (n¼ 18) and at 20C 1.495 0.05 times (n ¼ 18) the force of
control fibers.
zy0, active stiffness and rigor stiffness of fibers withmutationR719W and the respective control fibers were determined at a speed of length release of ~2–3 103
(nm/half-sarcomere)s1.increase in rigor stiffness of 45 5 13% (mean 5 SE; p <
0.05) was found (rigor stiffness of corresponding control
fibers 12.9 5 2.6 kPa/nm (n ¼ 7); Table 2; see Ko¨hler
et al. (10)). Mutation R723G also was associated with
a significantly greater fiber stiffness in rigor compared to
control fibers. The increase was 43 5 21% (p < 0.05) for
fibers from patient H27 and 595 15% (p< 0.001) for fibers
from patient H28 (rigor stiffness of control fibers 17.75 2.7
kPa/nm (n ¼ 6); Table 1). Soleus muscle fibers from the two
patients with mutation I736T showed only a much smaller,
statistically not significant increase in rigor stiffness by 95
9% for patient H19 and by 155 14% for patient H20 (same
controls as for R723G; Table 1). Almost identical effects
of the different mutations on fiber stiffness in rigor were
also observed at a lower speed of stretch of ~40 (nm/half-
sarcomere)s1 (data not shown).
Because in rigor at any one moment essentially all myosin
heads are attached to actin with very high affinity (16–18), an
increase in fiber stiffness most likely is not due to differences
in the fraction of attached cross-bridges, e.g., caused by faster
attachment to actin (kþ). Because, in addition, fiber stiffness
in rigor is essentially independent of the speed of the applied
stretch, e.g., at 3–5 103 (nm/half-sarcomere)s1 vs. 40 (nm/
half-sarcomere)s1, the observed differences in rigor stiffness
can also not be due to differences in the rate constant for disso-
ciation of rigor cross-bridges from actin (k; (44)). The
increase in rigor stiffness of soleus fibers with mutations
R719W and R723G, respectively, rather indicates that these
mutations are associated with higher cross-bridge stiffness,
i.e., a higher resistance to elastic distortion of the individual
myosin heads (S*). Note that rigor stiffness is not affected
by presence/absence of Mg2þ-ions (rigor solution with
2 mM free Mg2þ-ions, no EDTA versus rigor solution with
2.5 mM EDTA, no free Mg2þ-ions; T. Kraft, unpublished
results). Thus, even if the structure of the light chain binding
domain were affected by free Mg2þ-ions, it apparently does
not affect fiber stiffness in rigor.Effects of the mutations on ﬁber stiffness during
isometric contraction
A change in stiffness of the individual cross-bridges (S*) due
to a mutation is expected to also cause a change in fiber stiff-
ness during isometric contraction. Fiber stiffness during
isometric contraction, however, can further be changed if
mutations affect cross-bridge cycling kinetics (Eq. 1) or actin
binding kinetics of the force generating cross-bridges. Fig. 1 B,
Table 1, and Table 2 show, for all three mutations and all five
patients, fiber stiffness measured during isometric contrac-
tion by imposing small ramp-shaped releases. The speed of
the applied length changes was ~2–5  103 (nm/half-
sarcomere)s1. Mutation R719W was associated with
a significant increase in stiffness of isometrically contracting
soleus muscle fibers by 485 15% (p < 0.05). Active stiff-
ness of the respective control fibers was 10.45 1.1 kPa/nm
(n ¼ 14; Table 2 and Ko¨hler et al. (10)). Similarly, active
stiffness of muscle fibers from patient H27 and patient
H28 with mutation R723G increased significantly by 32 5
10% (p < 0.05) and 43 5 19% (p < 0.05), compared to
active stiffness of control fibers that was 13.25 1.7 kPa/nm
(n ¼ 9; Table 1). Active stiffness of soleus fibers with
mutation I736T was not significantly different from active
stiffness of control fibers. Note that data for fibers with muta-
tion R719W and the corresponding group of control fibers
(Table 2) were obtained in earlier experiments with some-
what differently composed solutions.
Unlike rigor, fiber stiffness observed during isometric
steady-state contraction depends on the speed of stretch,
presumably due to cross-bridges progressing to subsequent
states in the ATPase cycle (2) and because of transient detach-
ment and rapid reattachment of force generating cross-
bridges (20). To exclude that the changes in fiber stiffness
observed during isometric contraction are caused by changes
in attachment/detachment kinetics or changes in progression
of cross-bridges to later states in their ATPase cycle, we alsoBiophysical Journal 97(3) 806–824
812 Seebohm et al.FIGURE 2 Stiffness of soleus muscle fibers recorded during isometric
contraction at different speeds of length change. Stiffness of muscle fibers
with myosin mutations R719W, R723G, and I736T, respectively, is shown
normalized to stiffness of control fibers at highest available speed of length
change. Filled symbols, controls; open symbols, fibers with mutation. (A)
Fibers with mutation R719W (n¼ 9) and control fibers (n ¼ 14). Difference
in stiffness at all speeds of length change significant (p< 0.05 or p< 0.01). (B)
Fibers withmutationR723G (n¼ 10) and control fibers (n¼ 9). Difference inBiophysical Journal 97(3) 806–824recorded stiffness-speed relations, i.e., the dependence of
fiber stiffness on the speed of the length changes applied to
the fibers in isometric steady-state contraction. If only the
stiffness per cross-bridge (S*) is affected by the mutations,
then fiber stiffness is expected to increase by a similar fraction
at all speeds of length change. Changes in the rate constant for
e.g., dissociation from actin (k) would cause a horizontal
shift in the stiffness-speed relation (44).
The stiffness-speed relations in Fig. 2, A–C, show that
mutation R719W as well as mutation R723G (shown here
for patient H27) are associated with an increase in active
fiber stiffness at all speeds of stretch. In contrast, no signifi-
cant difference, compared to control fibers, was found for
active stiffness of soleus fibers with mutation I736T (shown
here for patient H20). Muscle fibers from the other two
patients, patient H28 with mutation R723G and patient
H19 with mutation I736T showed similar curves with and
without an increase in active stiffness, respectively (data
not shown). Solid lines in Fig. 2, A–C, show linear fits to
the different stiffness-speed relations. The small shifts in
the intercept with the abscissa for mutations R719W and
R723G show that for both mutations only a small, at most
three- to fivefold decrease in the rate constant for transient
dissociation from actin or quick tension recovery may
contribute to the increased active stiffness (44). The dashed
lines with unchanged intercept on the abscissa show that for
both mutations, stiffness-speed relations of controls and
mutants can almost equally well be accounted for without
any horizontal shift, i.e., without assuming approximately
three- to fivefold slower rate constants for transient detach-
ment or quick tension recovery.Nevertheless, even if this shift
would be considered to be real, it could not fully account for
the observed increase in stiffness during isometric contrac-
tion, but at most for 20–25% of it. These findings imply that
at least the major part of the increase in active fiber stiffness
seen with mutations R719W and R723G, respectively, is
due to changes in S*, i.e., a higher resistance to elastic distor-
tion of the individual myosin heads, as implied by the
increased stiffness seen under rigor conditions.
At this point, however, it is not excluded that mutations in
the converter domain may also be associated with some
changes in cross-bridges turnover kinetics during active
contraction, that may contribute to the changes in fiber stiff-
ness observed during isometric contraction.
stiffness at all speeds of length change significant (p < 0.05 or p < 0.01),
except for the slowest speed. (C) Fibers with mutation I736T (n ¼ 11) and
control fibers (n¼ 9); no statistically significant difference between stiffness
of mutated and control fibers (p> 0.05). Solid lines represent linear fits to the
respective data points; in C to controls. Broken lines in A and B are derived
from the fits to the data points of the fibers withmutation, but vertically scaled
down to match the control data. Note that broken lines still fall inside SE-
range of controls, i.e., plots for fibers with mutation and for control fibers
could be fitted without difference in intercept with abscissa. In some cases
error bars are smaller than symbol. T ¼ 10C, all data mean5 SE.
Cross-Bridge Compliance in Converter 813Effects of the mutations on isometric force
If mutations increase stiffness of an individual myosin head,
it is expected that isometric force is also increased. The
increase in force should be proportional to the increase in
stiffness of the individual myosin head, unless i), the extent
of elastic distortion of a force generating cross-bridge (y0*) is
also changed; or ii), the fraction of cross-bridges in strong-
binding, force generating states is also highly affected
(Eqs. 2a and 2b).
Thus, as the next step we measured active isometric force
in comparison to fiber stiffness in rigor and fiber stiffness
seen during isometric contraction. Fig. 3, Table 1, and Table
2 footnote show isometric force of fibers with mutations
R723G, I736T, and R719W, respectively, normalized to
maximum force generation of fibers from controls. For muta-
tion R719W a substantial increase in force by 595 7% and
49 5 5% compared to controls at 10C and 20C, respec-
tively, was observed. Fmax of the corresponding control
fibers was 72.65 4.05 kPa (n ¼ 19) at 10C and 130.495
6.72 kPa (n ¼ 19) at 20C (Table 2; Ko¨hler et al. (10)).
These values are quite similar to the 435 2% force increase
(20C) observed with mutation R719W in a recent set of
experiments when fiber ATPase activity was determined
with different solution composition (Fig. 3, Table 1). For
mutation R723G, patient H27 a smaller, but also significant
increase in isometric force by 23 5 5% and 19 5 1% at
10C and 20C, respectively, was found (p < 0.001; Fmax
of controls was 108.945 5.31 kPa (n ¼ 36) and 140.865
FIGURE 3 Effects of myosin head domain mutations on isometric force.
Mean values (5SE) normalized to isometric force of fibers from healthy
controls. T ¼ 20C. Control fibers n ¼ 45; Mutation R719W n ¼ 14
(Fmax data from Table 1); mutation R723G n ¼ 7 fibers of patient H27
and n ¼ 14 fibers of patient H28; mutation I736T n ¼ 7 fibers of patient
H19 and n ¼ 20 fibers of patient H20. For fibers with mutations R719W
and R723G, respectively, a significant increase in isometric force generation
was found (p < 0.001). Asterisk indicates statistically significant difference
compared to controls. For absolute values see Table 1 and Table 2, sample
force trace is shown in Fig. 6.1.25 kPa (n ¼ 45) at 10C and 20C, respectively; Table 1).
Muscle fibers with the same mutation but from patient H28
showed a similar increase in isometric force (Table 1).
Muscle fibers from the two patients with mutation I736T
showed no significant change in isometric force generation.
The lack of change in isometric force for mutation I736T,
and the increase in isometric force for mutations R719W
and R723G qualitatively agree with the data for fiber stiff-
ness in rigor and during isometric force generation. The
magnitude of the increase in isometric force of fibers with
mutation R723G, however, is only about half of the increase
in fiber stiffness, whereas the increase in isometric force of
the R719W mutation, in contrast, is about as large as the
increase in isometric stiffness.
Effects of the mutations on the y0–value
The discrepancies between increase in isometric force and
fiber stiffness recorded in rigor or isometric contraction raise
the question whether the extent of elastic distortion of the
individual cross-bridge during force generation, y0*, may
be differently affected by the two mutations (Eq. 2b). We
therefore determined for control fibers and fibers with the
different mutations the minimum extent of filament sliding
necessary to drop isometric force to zero, y0. Fig. 4 shows
original plots of force versus change in sarcomere length
during ramp-shaped releases imposed on isometrically con-
tracting muscle fibers (T-plots (20,21)). Lines were fitted to
the initial linear parts of the plots (length change, 1.5–2
nm/half-sarcomere). The slopes of these lines represent
apparent fiber stiffness. The x axis intercepts of the fitted
lines indicate the minimum change in half-sarcomere length,
i.e., the minimum distance of filament sliding, necessary to
drop isometric force to zero (y0-value (23)).
The y0-value of fibers with mutation I736T on average
was not significantly different from control fibers; an
example of a T-plot is shown in Fig. 4 B. This is consistent
with the observation that mutation I736T neither affects
isometric force generation nor fiber stiffness in rigor or under
isometric steady-state contraction (Table 1, Figs. 1–3). The
y0-values for the fiber with mutation R723G and for the
control fiber shown here are also very similar (Fig. 4 A).
On average, the x axis intercepts at 10C were 8.53 5
0.42 nm/HS (n ¼ 6) and 7.70 5 0.74 nm/HS (n ¼ 9) for
control fibers and fibers with mutation R723G, respectively
(Table 1). Although the difference is not significant, the
data suggest that for fibers with mutation R723G the length
change necessary to drop active force to zero (i.e., the elastic
extension of attached mutated cross-bridges plus elastic
extension of myofilaments) is reduced by some 10%
compared to controls. For mutation R719W, it was shown
previously (Table 2; (10)) that the y0-values for fibers with
the mutation and for control fibers were also not significantly
different. However, a small increase in y0 for fibers with
mutation of <10% from 7.09 5 0.57nm/HS (n ¼ 14) forBiophysical Journal 97(3) 806–824
814 Seebohm et al.controls to 7.665 0.99 nm/HS (n ¼ 9) for fibers with muta-
tion R719W was observed (T ¼ 10C). Thus, both the
R719W and R723G mutation only slightly affect the mi-
nimum distance of filament sliding needed to drop isometric
force to zero. To estimate the changes in mean elastic exten-
sion of the mutated heads (y0*) from the observed y0-values,
however, both myofilament compliance and the fraction of
FIGURE 4 Original records of stiffness measurements during isometric
contractionof soleusmuscle fibers. Force is plottedversus change in sarcomere
length recorded during the imposed releases (T-plots); speed of length change
~3  103 (nm/HS)s1 for fibers with mutation (gray dots) and control fibers
(black dots), respectively. T ¼ 10C. Solid and broken lines: fits to the initial
linear parts (initial 1.5–2 nm/HS) of the T-plots and extended toward abscissa.
Broken lines, control fibers; solid lines, fibers withmutation. Intercept of fitted
curves with abscissa indicates y0-value of fibers, i.e., the minimum length
change necessary to drop active force to zero if no quick tension recovery
were present. (A) Fiber with mutation R723G (patient H27) and control fiber.
On average, y0-value for fibers with mutation R723G was ~10% smaller than
for control fibers. This difference, however, was statistically not significant.
Fmax of control fiber was 93 kPa. (B) Fiber with mutation I736T and control
fiber. The plots essentially superimpose. On average, no difference in stiffness
or y0 was detectable between fibers with mutation I736T and control fibers.Biophysical Journal 97(3) 806–824mutated heads in these fibers (14) have to be considered
(see Discussion).
For an estimate of filament compliance we measured fiber
stiffness and force during isometric steady-state contraction
of slow fibers of M. soleus muscle fibers from controls at
different levels of calcium-activation (from pCa 4.5 to pCa
6.6; Fig. 5). Fiber stiffness was measured in ramp-shaped
releases (T-plots; (20,21), see also Fig. 4) and the y0-values
were determined. In Fig. 5 isometric force is plotted versus
y0. Fmax of this set of control fibers was 112.955 0.11 kPa
(10C), y0 at maximum activation was 8.53 5 0.42 nm/HS
(n ¼ 3–6 fibers). A line was fitted to the data points that
had a y axis intercept at 5.67 nm/HS. From this filament
compliance per half-sarcomere could be calculated that
was 1/(112.95 kPa/(8.53 nm  5.67 nm)) ¼ 0.025 nm/kPa.
Effects of the mutations on cross-bridge
cycling kinetics
The data from measurements of fiber stiffness in rigor and
during active contraction hint toward an increase in cross-
bridge stiffness, S*, for the R719W and R723G mutations
whereas cross-bridges with the I736T mutation appear nearly
unaffected. The data of active isometric force qualitatively
agree with this notion, although the increase in force of the
R723G mutation appears on the low side. At this stage,
however, it is not excluded that the three mutations may
(also) be associated with some changes in cross-bridge
cycling kinetics during isometric contraction.
To characterize cross-bridge cycling kinetics of soleus
fibers with and without mutation, the rate constant of force
FIGURE 5 Relation of the extent of filament sliding necessary to drop
isometric force to zero (y0) vs. Fmax at different levels of calcium-activation.
The y0-value was derived from isometric force and active fiber stiffness that
was measured in ramp-shaped releases imposed on slow fibers of M. soleus
of control individuals during isometric steady-state contraction (T-plots;
(20,21)), see also Fig. 4) at pCa values from pCa 4.5 to pCa 6.6 (10C).
Speed of length release was 4–5  103 (nm/half-sarcomere)s1 on average.
Fmax¼ 112.955 0.11 kPa, y0 at maximum activation was 8.535 0.42 nm/
HS (n ¼ 3–6 fibers). Continuous line obtained by linear regression. Y axis
intercept of fitted line at 5.67 nm/HS. This indicates filament compliance
per half-sarcomere of 1/(112.95 kPa/(8.53 nm 5.67 nm))¼ 0.025 nm/kPa.
Cross-Bridge Compliance in Converter 815redevelopment after a short period of unloaded shortening
(kredev; Eq. 3), fiber ATPase activity during maximum
isometric force generation (Eq. 4), and maximum shortening
velocity (vmax) were determined. In Table 1 the results of
these experiments for the different mutations and the di-
fferent patients are listed. The data are normalized to values
of soleus muscle fibers from control individuals. Fig. 6 B
shows kredev of muscle fibers with the different mutations
and of control fibers. kredev for control fibers was 0.27 5
0.02 s1 (n ¼ 36) and 2.69 5 0.06 s1 (n ¼ 45) at 10C
FIGURE 6 Rate constant of force redevelopment (kredev). (A) Sample data
trace of isometric force and force redevelopment of a control fiber (20C)
recorded with a ‘‘release/restretch’’ protocol established previously
(37,60). The isometrically contracting fiber is subjected to a short period
(100 ms) of unloaded shortening followed by rapid restretch to isometric
fiber length. kredev is determined from the time course of force redevelop-
ment to the isometric steady state, assuming a single exponential function.
Isometric force obtained as difference between force in isometric steady state
and force level reached during the period of unloaded shortening. CSA of
this fiber, 12,000 mm2, kredev ¼ 2.94 s1. (B) Effects of mutations
R719W, R723G, and I736T on kredev. n ¼ 7–45 fibers. Note that no signif-
icant effect of the different mutations on kredev both at 10
C and 20C was
found (data for 10C not shown). Mean values (5SE) normalized to values
of control fibers. For absolute values see Table 1.and 20C, respectively. None of the mutations affects kredev
significantly. Fig. 7 B shows that the ATPase activity of
isometrically contracting soleus muscle fibers with the muta-
tions R723G and I736T is not different from control fibers.
ATPase activity in control fibers was 0.95 5 0.02 ATP/
(S1*s) at 20C (n ¼ 21; Table 1). However, with mutation
R719W, fiber ATPase is significantly increased by 21 5
2% (p < 0.001). This indicates that mutation R719W to
some extent affects cross-bridge cycling kinetics because
FIGURE 7 Fiber ATPase activity of controls and fibers with mutation. (A)
Pen recorder trace representing fiber ATPase activity of a control fiber
during maximum calcium activation (20C). Trace shows concentration of
NADH, obtained from absorbance at 360 nm and calibration with NADH
test solutions. For composition of preactivating and activating solution see
Methods. Decrease of NADH-absorbance is due to rephosphorylation of
ADP, that was coupled to reduction of pyruvate to lactate by oxidation of
NADH to NADþ. With calibration of the system the change in absorbance
could be converted to pmoles of NADH and thus MgADP produced by the
fiber per second. ATPase activity was calculated based on ADP generation,
fiber volume, and an S1-content of 154 pmol S1/mL fiber volume (50). CSA,
8700 mm2; fiber length, 2 mm; ATP-turnover per myosin head in this fiber
was 0.85 ATP/s, Fmax was 144 kPa. (B) Effects of mutations R719W,
R723G, and I736T, on ATPase activity of fibers during isometric contraction
(n ¼ 6–21 fibers). T ¼ 20C to enhance signal/noise for ATPase measure-
ments. Mean values (5SE) normalized to values of control fibers. For abso-
lute values see Table 1. Asterisk indicates statistically significant difference
to controls. Fiber ATPase activity is significantly affected only by mutation
R719W (p < 0.001).Biophysical Journal 97(3) 806–824
816 Seebohm et al.ATPase activity (Eq. 4) is not expected to be sensitive to
changes in S* or F*, two parameters that could account for
changes in fiber stiffness and changes in active force. The
increase in isometric fiber ATPase could result from e.g.,
an increase in gapp that would tend to decrease active force,
or an increase in fapp that would tend to increase active force.
vmax of isotonically shortening soleus muscle fibers with
the different mutations in comparison to vmax of control
fibers is shown in Table 1 and Fig. 8 B. vmax of control
fibers was 329.95 8.61 (nm/HS)s1 (n ¼ 10) and 32465
86.79 (nm/HS)s1 (n ¼ 7) at 10C and 20C, respectively.
For mutation R719W and mutation R723G a slight increase
in vmax was found that was significant only for fibers with
mutation R723G from patient H28 (p % 0.05). Data from
fibers of the second patient with mutation R723G and of
the patient with the R719W mutation only show a nonsignif-
icant trend toward higher vmax. For the I736T mutation no
effect on vmax was observed. This indicates that mutations
R719W and R723G may affect cross-bridge turnover under
isotonic conditions to some extent. The slight increase in
vmax could reflect an increase in g2app, the rate constant for
the transition of the cross-bridges back to the nonforce gener-
ating states during unloaded shortening.
DISCUSSION
Mutations R719W and R723G reveal the converter
domain as the major element of cross-bridge
compliance
The increase in rigor stiffness of muscle fibers with either
point mutation R723G or, as shown before, with mutation
R719W, can be attributed to a substantial increase in stiff-
ness of the individual mutated myosin heads (S*). An
increased cross-bridge stiffness and thus an increased fiber
stiffness, however, can only be caused by an increased stiff-
ness of the most compliant part of the myosin head domain.
An increase in stiffness of a more rigid element, in contrast,
would have essentially no effect on overall stiffness of
a cross-bridge or on fiber stiffness. This is because overall
stiffness of the acto-myosin complex is limited by stiffness
of the element(s) with the smallest resistance to elastic distor-
tion, i.e., the most compliant element(s) of this complex.
Because both mutations, R719W and R723G are located
inside the converter domain of the myosin head, the
increased stiffness in rigor and isometric contraction indi-
cates that most of the elastic distortion of the cross-bridges
occurs in the converter domain or in structural elements
closely related to the converter. Consequently the converter,
or at least converter-associated structures that are influenced
by amino acids R719 and R723, respectively, represent
compliant structural elements of the cross-bridge where
main elastic distortion occurs. This conclusion is consistent
with observations from electron microscopy and single
particle analysis on myosin V HMM molecules where flexi-Biophysical Journal 97(3) 806–824bility between motor domain and lever arm near the
converter subdomain had to be postulated to accommodate
the different conformations of the two actin-attached heads
FIGURE 8 Maximum unloaded shortening velocity (vmax) of control
fibers and fibers with mutation. (A) Sample data traces of slack test experi-
ments (39,40)) to determine vmax of a control fiber at 20
C. The time
required by the fiber to shorten until the imposed slack is taken up, i.e., until
force starts to redevelop, is plotted versus the amplitude of the length
change, as indicated by the four data points. Usually at least 10 slacks of
different amplitudes were applied to a fiber to obtain the shortening curve.
Every slack was followed by a release/restretch maneuver (cf. Fig. 6) to
avoid restretching the fibers to isometric length after partial redevelopment
of force. vmax, i.e., the initial slope of the shortening curve, is determined
by curve fitting. Length of fiber shown here, 3000 mm; sarcomere length
2.4 mm; CSA, 8500 mm2; amplitude of slacks from top to bottom 14%,
22%, 26%, and 36% of fiber length, respectively. Time of slack until start
of force increase from left to right 45 ms, 104 ms, 136 ms, and 247 ms,
respectively. vmax of this fiber was 3450 (nm/HS)s
1. (B) Effects of muta-
tions R719W, R723G, and I736T on vmax; n ¼ 6–11 fibers. T ¼ 20.
Note effects of mutations on vmax essentially identical for both, 10
C and
20C (data for 10C not shown). Mean values (5SE) normalized to values
of control fibers. For absolute values see Table 1. Asterisk indicates statisti-
cally significant difference to controls. A statistically significant change in
vmax compared to controls (p % 0.05) was only found for fibers of patient
H28 (mutation R723G).
Cross-Bridge Compliance in Converter 817(45). The absence of strongly curved lever arms in the recon-
structions is consistent with elastic deformation within the
converter rather than in the light chain binding domain.
Mutation I736T had neither a significant effect on fiber
stiffness nor on force generation. Only a small, statistically
not significant increase in rigor stiffness was observed.
This implies that this mutation does not affect the elastic
distortion of the myosin head domain substantially. The
missing effect of mutation I736T on any of the measured
parameters could be due to the different location within the
converter region. Amino acid I736 is located at some
distance from residues R719 and R723 toward the surface
of the converter (Fig. 9; cf. structures published by Houdusse
et al. (28) and Rayment et al. (29)). Aside from this, the rela-
tively low abundance of mutated myosin (37% on average
(46)) in the contractile system of the I736T biopsies may
yield smaller effects on functional parameters than R719W
or R723G do, with an average abundance of mutated myosin
of 54% and 62%, respectively (14,46).
Amino acids 719 and 723, in contrast, are located in the
core of the converter in a helix with close contacts to the first
turns of the long a-helix in the atomic models of the myosin
head domain of both scallop and chicken (Fig. 9; (28,29)).
Both mutations, R719W and R723G, cause a loss of positive
charge and an increase in hydrophobicity. The converter
FIGURE 9 Ribbon diagram of the converter region with adjacent parts of
catalytic and light chain binding domains. Catalytic domain points to upper
right, light chain binding domain toward left. Chicken skeletal muscle
myosin (adapted from Rayment et al. (29)). Long a-helix of light chain
binding domain in yellow; relay helix of catalytic domain in cyan. Residues
equivalent to amino acids R719 (red), R723 (green), and I736 (magenta) in
the human sequence are shown in space-filling representation. Note that resi-
dues equivalent to R719 and R723 are located in a helix parallel to and in
close contact with the long a-helix of light chain binding domain. Also
note that 723 is very close to the essential light chain. The residue equivalent
to I736 is located further away at the surface of the converter. Essentially the
same arrangement is found in the scallop structure of Houdusse et al. (28) if
sequences are properly aligned (þ2 residues for chicken, 2 residues for
scallop). In the scallop structure, however, position equivalent to 736 is at
the start of a gap in the polypeptide chain at the surface. Figure prepared
using RasMol.forms a socket for the lever arm, and the anchoring of the
long alpha helix in the converter seems to be stabilized by
hydrophobic patches (28). Thus, both R719W and R723G
mutations might well form an even more stable anchoring
socket for the long alpha helix of the light chain binding
domain, i.e., with mutation R719W and R723G the converter
may now act as a less compliant anchoring element. In addi-
tion, residue 723 is very close to the essential light chain
(Fig. 9). Interactions of parts of the converter with the essen-
tial light chain might further stabilize elastic anchoring of the
lever arm in the converter. This again would place R723
together with R719 at a critical point for resistance to elastic
distortion in the complex formed by the converter with the
a-helix of lever arm and the essential light chain (Fig. 9).
The high similarity in the location of residues equivalent to
human b-cardiac R719 and R723 residues in both scallop
and chicken structure suggest that in cardiac muscle a similar
structural organization may be found, but the crystal struc-
ture of the b-cardiac head domain is required to clarify this
point.
Our data on mutations within the converter domain, that
occur naturally in HCM, not only suggest strongly that the
converter domain is the main structural element of cross-
bridge where elastic distortion occurs but also show that an
amino acid exchange within the converter can change
cross-bridge stiffness quite substantially. Sequence compar-
ison of different class II myosins shows that several residues
within the converter are not conserved, including residues
equivalent to R719, R723, and I736 of the b-cardiac myosin
heavy chain. Because even a single amino acid exchange, at
least at some of these positions, quite significantly affects
cross-bridge elasticity, our data raise the possibility that the
extent of elastic distortion of the myosin head on generation
of motile forces may be quite different for different myosins,
i.e., may specifically be tuned to different functional require-
ments.
Changes in cross-bridge cycling kinetics cannot
explain larger isometric force with mutations
R719W and R723G
In addition to the increase in fiber stiffness under rigor
conditions, we also found some effects of mutations R723G
and R719W on parameters of cross-bridge cycling kinetics.
Mutation R719W was associated with a 21% increase in
ATPase activity along with the much larger increase in Fmax
by at least 43% and an increase in active fiber stiffness by
48%. An increase in fiber ATPase could be due to changes
in cross-bridge cycling kinetics, i.e., fapp and/or gapp, or an
increase in n, the total number of turning-over cross-bridges
per half-sarcomere (Eq. 4). The second possibility, an
increase in n, has previously been ruled out for mutation
R719W (10). No differences in packing of myofibrils or
myofilaments compared to controls was found. In addition,
it was shown for HCM mutations R403Q and R249QBiophysical Journal 97(3) 806–824
818 Seebohm et al.expressed in rat cardiomyocytes that there was no effect of
these mutations on assembly of the thick filaments and forma-
tion of the sarcomeres (15). This indicates that effects ofHCM
point mutations in the myosin head domain on assembly of
thick filament and therefore on n are quite unlikely.
The increase in ATPase activity of fibers with mutation
R719W most likely is due to changes in fapp and/or gapp. In
principle, an increase in fiber ATPase can be caused by an
increase in fapp, or an increase in gapp, or changes in both
rate constants. However, such changes will also affect kredev
and Fmax (Eqs. 2a and 3). When we calculated changes in
ATPase, kredev, and Fmax for various changes of fapp and/or
gapp we found that an increase in fapp by 42% and an increase
in gapp by 7% resulted in an increase in ATPase activity by
21%, as measured experimentally, and an increase in kredev
that remains close to the limits of the measured SD-values
of kredev. This possible increase in fapp and gapp, however,
would only cause an increase in Fmax by 13%. Other combi-
nations of changes in fapp and gapp that yielded larger
increases in Fmax were inconsistent with the observed
ATPase and/or kredev data. Thus, it was not possible to fully
account for the at least 43% increase in isometric force by
kinetic changes alone. Kinetic changes can at most
contribute a 10–15% increase in isometric force and a corre-
sponding increase in active fiber stiffness by a higher occu-
pancy of force generating states. The remaining increase in
force and active fiber stiffness for mutation R719W suggests
a change in F*, the contribution of individual force-gener-
ating cross-bridges to isometric force.
Measurements of kredev and isometric fiber ATPase for
mutation R723G did not show any significant changes in
cross-bridge cycling kinetics. Therefore, the increase in
Fmax (20
C) with this mutation by 19% and 22%, respec-
tively, implies an increase in F*. It is unlikely that changes
in cross-bridge cycling kinetics, e.g., in kredev, were masked
by increased elastic extension of myofilaments resulting
from the higher active forces generated by cross-bridges
with mutation R723G. In previous work, we had measured
kredev when active force at saturating Ca
2þ was inhibited by
different extent, either by the actin binding fragment of cal-
desmon (34,47) or by incubation with N-ethylmaleimide-
modified myosin subfragment 1 (48). Inhibition of active
force by competition with binding of N-ethylmaleimide-
modified myosin subfragment 1 to actin had no effect on
the observed kredev at saturating Ca
2þ, inhibition of active
force by the actin binding fragment of caldesmon reduced
kredev at saturating Ca
2þ by at most 10–15%. Thus, changes
in elastic extension of filaments by changing active force other
than by Ca2þ concentration seems to have little if any effect
on kredev.
The increase in maximum unloaded shortening velocity
under isotonic conditions (vmax) by 7–17% for mutations
R723G and R719W, although not significant except for
patient H28 with mutation R723G, indicates that these two
mutations may affect cross-bridge turnover kinetics underBiophysical Journal 97(3) 806–824isotonic conditions to some extent. Shortening velocity is
primarily limited by the rate constant of the transition of
the cross-bridges back into the nonforce generating states,
g2app, at the end of the power stroke (1). Therefore, our
results indicate that mutation R719W and R723G might
slightly speed up this transition of the cross-bridges under
isotonic conditions that is coupled to strain-dependent
release of ADP from the active site (25) and binding of
a new ATP molecule (26).
In summary, the observed changes in cross-bridge cycling
kinetics can only account for a small part of the increase in
isometric forceand isometricfiber stiffness observedwithmuta-
tion R719W. The major effect of both mutations, R719W and
R723G, however, most likely is an increase in force contribu-
tion and in stiffness of the individual myosin head, F* and S*.
Effects of mutations R719W and R723G
on stiffness S* and force F* of individual
cross-bridges
Observed fiber stiffness depends on i), stiffness (resistance to
elastic distortion) of the individual cross-bridges (S*); ii), the
number of myosin heads attached to actin at the moment of
measurement; and iii), myofilament compliance. Mutations
in the converter domain of the myosin head most likely do
not affect myofilament compliance. Therefore, the increase
in fiber stiffness in rigor, where all myosin heads are
supposed to be attached to actin with high affinity, indicates
that mutations R719W and R723G increase stiffness of the
individual mutated myosin heads.
To estimate changes in the stiffness of rigor cross-bridges
with mutation R723G from the observed changes in fiber
stiffness (Table 1), filament compliance needs to be consid-
ered. For this estimate we measured fiber stiffness and force
during isometric contraction of soleus muscle fibers from
controls at different levels of calcium-activation and deter-
mined filament compliance per half-sarcomere that was
0.025 nm/kPa at 10C (Fig. 5). This is almost identical
with the value published previously for human slow muscle
fibers (49). From rigor stiffness of control fibers (17.7 kPa/
nm; Table 1), half-sarcomere compliance of control fibers
in rigor is 1/17.7 ¼ 0.056 nm/kPa. Thus, compliance of
the population of attached rigor cross-bridges per half-sarco-
mere of control fibers is 0.056–0.025 ¼ 0.031 nm/kPa; i.e.,
their stiffness is 31.75 5 9.6 kPa/nm (n ¼ 6). Based on
~111  103 myosin heads/mm2 in a half-sarcomere of a skel-
etal muscle fiber, which can be derived from myosin concen-
tration in muscle fibers (50) and that is very similar to the
value derived from filament lattice dimensions in Linari
et al. (115  103 myosin heads/mm2 in a half-sarcomere)
(51), rigor stiffness of individual heads in the slow skeletal
muscle fibers of control individuals is 0.29 5 0.09 pN/nm
(Table 3; 31.75 1015 pN/(m2 nm)/111 1015 heads/m2).
For mutation R723G, patient H27, fiber stiffness in rigor
is 1.43 times the stiffness of control fibers (Table 1). Thus,
Cross-Bridge Compliance in Converter 819TABLE 3 Estimates of stiffness per myosin head (S*), force per myosin head (F*), and y0 of individual myosin heads (y0*) calculated
from half-sarcomere stiffness (after subtraction of ﬁlament compliance) and isometric force generated by the soleus muscle ﬁbers
Mut R719W* Controls for Mut R719W* Mut R723Gy(H27) Controls for Mut R723Gy
Stiffness per head in rigor (pN/nm) 0.45 0.17 0.84 0.29
Isometric stiffness per head at 10C (pN/nm) 0.39 0.19 0.52 0.28
Isometric force per head at 10C (pN) 1.77 0.99 1.99 1.49
Isometric force per head at 20C (pN) 2.88 1.77 2.56 1.92
y0 per head at 10
C (nm) 4.54 5.14 3.83 5.32
Calculations are based on a filament compliance of 0.025 nm/kPa (Fig. 5). Force and stiffness per head during isometric contraction were calculated based on
111  103 myosin heads/mm2 in a half-sarcomere and a fraction of strongly bound myosin heads of 0.66 (52).
For the two controls (that were measured under slightly different conditions) the values for stiffness per head in rigor (0.175 0.05 pN/nm, (n¼ 7) and 0.295
0.09 pN/nm (n ¼ 6)) and isometric contraction (0.19 5 0.04 pN/nm, (n ¼ 14) and 0.28 5 0.07 pN/nm (n ¼ 9)) were not significantly different (all
values5 SE).
*Calculations based on a fraction of 54% of myosin heads with mutation R719W, 46% wild-type heads (46), and on the values for force and stiffness shown in
Table 2 (see also 10). For mutation R719W, changes of cross-bridge turnover kinetics were also taken into account that contribute an increase in Fmax and in
active fiber stiffness of ~15%.
yCalculations based on a fraction of 62% heads with mutation R723G, 38% wild-type heads (14), and on values for force and stiffness shown in Table 1.total half-sarcomere compliance of R723G-fibers of this
patient in rigor is 1/25.3 ¼ 0.0395 nm/kPa. Assuming
unchanged filament compliance, the compliance of rigor
cross-bridges in fibers with mutation R723G is 0.0395–
0.025 ¼ 0.0145 nm/kPa, i.e., their stiffness is 68.9 kPa/nm.
According to our protein quantification data, in muscle
with the R723G mutation 38% of the cross-bridges are
wild-type cross-bridges (stiffness, 31.75 kPa/nm) and 62%
of the cross-bridges have the R723G-mutation (14). To
obtain a stiffness of the mixed cross-bridge population in
rigor of 68.9 kPa/nm, a pure population of R723G cross-
bridges needs to have a stiffness in rigor of 91.8 kPa/nm.
Assuming that cross-bridges with the R723G-mutation are
also all attached to actin in rigor, as the wild-type cross-
bridges, i.e., that the number of attached cross-bridges is
unchanged, the above estimate implies that the stiffness of
the individual cross-bridge with mutation R723G in rigor
(S*rigor 723) is ~2.9 times larger than the stiffness of the
wild-type cross-bridge (S*rigor WT), i.e., 0.84 pN/nm (Table 3).
In earlier measurements on mutation R719W and controls
with solutions of somewhat different composition (Table 2;
(10)) compliance of rigor cross-bridges per half-sarcomere
of control fibers was 0.0775–0.025 ¼ 0.0525 nm/kPa; i.e.,
their stiffness was 19.05 5 6.1 kPa/nm (n ¼ 7) that corre-
sponds to 0.17 5 0.05 pN/nm for individual myosin heads
(Table 3). These values are not significantly different from
stiffness of the group of control fibers for mutation R723G
(Tables 1 and 3). The difference in stiffness for the two
groups of control fibers can be related to different levels of
force where stiffness measurements were done most likely
due to differences during the transition of the fibers into
rigor at slightly different experimental conditions. Fibers
with mutation R719W, on average, had 1.45-fold higher
fiber stiffness in rigor compared to controls (Table 2). Based
on this and the same estimate as shown above, compliance of
rigor cross-bridges in fibers with mutation R719W is
0.053–0.025 ¼ 0.028 nm/kPa, i.e., their stiffness is 35.1
kPa/nm. If we consider that in these fibers 54% of myosinheads carried mutation R719W (46), a pure population of
R719W cross-bridges needs to have a stiffness in rigor of
48.8 kPa/nm to obtain a stiffness of 35.1 kPa/nm of the
mixed cross-bridge population in fibers of the patient with
mutation R719W. This indicates that the stiffness of
a cross-bridge with R719W mutation in rigor (S*rigor 719) is
~2.6 times larger than the stiffness of the cross-bridges in
the respective group of control fibers (S*rigor WT), i.e., 0.45
pN/nm (Table 3).
Next we asked whether data of fiber stiffness of mutation
R723G recorded during isometric contraction (Table 1) yield
a similar change in stiffness of force-generating cross-
bridges. First we estimated the stiffness of force-generating
cross-bridges of control fibers at 10C along the same lines
as we did for stiffness in rigor. Fiber stiffness of control
fibers during isometric contraction is ~13.2 kPa/nm (Table
1), i.e., half-sarcomere compliance is 0.076 nm/kPa. With
filament compliance per half-sarcomere of 0.025 nm/kPa
(Fig. 5), compliance of the force generating wild-type
cross-bridge population is 0.076–0.025 ¼ 0.051 nm/kPa.
Hence their stiffness is 19.7 5 5.1 kPa/nm (n ¼ 9), which
corresponds to 0.18 5 0.05 pN/nm for individual force
generating cross-bridges in slow skeletal muscle fibers of
controls at 10C. Yet, if we consider a fraction of strongly
attached cross-bridges in isometric contraction of 0.66, as
observed previously (52), then stiffness of the individual
myosin heads in soleus muscle of control individuals is
0.28 pN/nm at 10C (Table 3).
Active stiffness of fibers from patient H27 with the R723G
mutation at 10C is 1.32 times the stiffness of control fibers
(Table 1), i.e., 17.4 kPa/nm. Hence half-sarcomere compli-
ance is 0.0574 nm/kPa, yielding a compliance of the popula-
tion of force-generating cross-bridges in fibers with mutation
R723G of 0.0574–0.025 ¼ 0.032 nm/kPa or a stiffness of
30.9 kPa/nm compared to the 19.7 kPa/nm for the force
generating cross-bridges in the control fibers. To obtain stiff-
ness of the force-generating cross-bridges with mutation
R723G we must consider that 38% of the myosin headsBiophysical Journal 97(3) 806–824
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Therefore, stiffness of a pure population of force generating
cross-bridges with mutation R723G is 37.7 kPa/nm. If we
take a fraction of strongly attached cross-bridges in isometric
contraction of 0.66 into account, then stiffness of an indi-
vidual mutated force generating cross-bridge (S*act 723) is
0.52 pN/nm (Table 3). This is 1.9-fold larger than the stiff-
ness of a force generating cross-bridge in control fibers
(S*act WT).
For a similar estimate of the increase in stiffness of force
generating cross-bridges with mutation R719W, the 1.48-
fold average increase in active fiber stiffness at 10C
(Table 2; (10)) together with a fraction of 54% of mutated
myosin heads as well as changes in cross-bridge cycling
kinetics have to be taken into account. Half-sarcomere stiff-
ness of the population of force-generating cross-bridges in
fibers with mutation R719W at 10C is 25.0 kPa/nm
compared to 14.15 3.0 kPa/nm (n ¼ 14) for cross-bridges
in the respective control fiber group (Table 2). In the control
fibers this corresponds to 0.135 0.03 pN/nm for individual
force generating cross-bridges. Taking into account a fraction
of strongly attached cross-bridges of 0.66, as observed previ-
ously for isometric contraction (52), stiffness of an indi-
vidual myosin head during force generation in this group
of control fibers is 0.19 pN/nm. Yet, we assume that for
mutation R719W ~1/3 of the observed increase in fiber stiff-
ness during isometric contraction is due to changes in occu-
pancy of force generating cross-bridges resulting from
effects of the R719W mutation on cross-bridge cycling
kinetics. Subtracting one-third from the stiffness increase
of force generating cross-bridges in fibers with mutation
R719W leaves an increase from 14.1 kPa/nm (control) to
21.4 kPa/nm (R719W) unaccounted by changes in cross-
bridge turnover kinetics. Assuming that the increase of
7.3 kPa/nm arises from higher stiffness of the cross-bridges
with mutation R719W we can estimate the necessary
increase in stiffness of the R719W-cross-bridges, consid-
ering that 46% of the myosin heads are of the wild-type
form, 54% with the R719W mutation. This yields a stiffness
of a pure population of force generating cross-bridges with
mutation R719W of 27.7 kPa/nm. Thus, stiffness of indi-
vidual force generating cross-bridges with mutation R719W
(S*act 719) is ~2-fold larger than the stiffness of a force gener-
ating cross-bridge (S*act WT) in the respective group of control
fibers (Table 2). This corresponds to 0.19 pN/nm and 0.39 pN/
nm per wild-type myosin head and per myosin head with
mutation R719W (Table 3), respectively, if a fraction of
strongly attached cross-bridges in isometric contraction of
0.66 is taken into account. If all the increase in fiber stiffness
were due to changes in cross-bridge stiffness, i.e., assuming
no significant change in the fraction of force-generating
cross-bridges by changes in cycling kinetics, a 2.4-fold
increase in stiffness of the force generating cross-bridge
with mutation R719W would be required to account for the
observed change in active fiber stiffness.Biophysical Journal 97(3) 806–824Thus, altogether, the data of fiber stiffness during isometric
contraction suggest that for both mutations cross-bridge stiff-
ness increases by about the same extent (~2-fold). In rigor the
increase is somewhat larger for cross-bridges with mutation
R723G (2.9-fold) compared to cross-bridges with mutation
R719W (2.5-fold).
With the twofold increase in half-sarcomere stiffness of
force generating cross-bridges we next can test whether this
observed change in half-sarcomere cross-bridge stiffness
can also account for the actually observed increase in
isometric force for mutations R719W and R723G. Observed
isometric force is proportional to the product of elastic distor-
tion of force generating cross-bridges, y0* (Eqs. 2a and 2b)
times the stiffness of themixed population of force generating
cross-bridges, i.e., abundance of wild-type cross-bridges
times stiffness of wild-type cross-bridges plus abundance of
mutant cross-bridges times stiffness of mutant cross-bridges.
For mutation R723G, patient H27, stiffness of the mixed
wild-type andmutant force generating cross-bridgepopulation
is 0.38 19.7 kPa/nmþ 0.62 37.7 kPa/nm¼ 30.9 kPa/nm
(10C). The minimum length change per half-sarcomere
required to drop active force to zero was 7.7 nm (Table 1).
This equals elastic extensionof filaments plus elastic extension
of cross-bridges. Elastic extension of filaments is filament
compliance times active force, i.e., 0.025 nm/kPa  1.23 
108.94 kPa ¼ 3.35 nm (10C; Table 1), yielding 7.7–3.35 ¼
4.35 nm of average elastic extension of cross-bridges at
10C.Thus, expected active force is 4.35nm 30.9 kPa/nm¼
134.4 kPa compared to the observed 1.23  108.94 kPa ¼
133.9 kPa.
For mutation R719W, where also a change in cross-bridge
cycling kinetics was observed, the same calculation with
a cross-bridge stiffness of the mixed population (54%myosin
heads with mutation, 46% wild-type myosin) of 21.4 kPa/nm
and a minimum length change per half-sarcomere required to
drop active force to zero of 7.66 nm (10C; Table 2; (10))
predicts 0.025 nm/kPa  1.59  72.6 kPa ¼ 2.89 nm,
yielding 7.66–2.89 ¼ 4.77 nm of average elastic extension
of cross-bridges at 10C. Thus, expected active force at
10C is 4.77 nm  21.4 kPa/nm ¼ 102.1 kPa compared to
the observed 115.4 kPa of mutated fibers (10C). We have,
however, to consider that we attributed a 15% increase in
fiber stiffness with mutation R719W to changes in cross-
bridge cycling kinetics. Thus, active force is expected to be
also increased ~1.15 times, yielding a total of 1.15 102.4¼
117.8 kPa. This essentially equals the observed isometric
force for fibers with the R719W mutation.
Thus, the changes in stiffness of the myosin head, esti-
mated from measurements of fiber stiffness can fully account
for the observed changes in active force. That active force
neither changes in proportion to active fiber stiffness nor in
proportion to stiffness of the population of force generating
cross-bridges is the result of filament compliance. With
increasing active force, filaments are extended more such
that elastic distortion of cross-bridges during isometric force
Cross-Bridge Compliance in Converter 821generation decreases. As a result, active force, assumed to be
generated by the elastic distortion of strongly bound cross-
bridges increases less than cross-bridge stiffness.
Even though for mutation I736T no significant effect on
any of the measured parameters was observed, a slight
increase in rigor stiffness by an average of 12% might indi-
cate some effect of this mutation on S*. In the soleus biopsies
of the two patients with mutation I736T, abundance of
mutated myosin heads was found to be 38% (14). If this frac-
tion of mutated myosin and the increase in rigor stiffness is
taken into account, stiffness of the individual myosin heads
with mutation I736T may have increased ~1.6-fold (based
on the values in Table 1 and filament compliance per half-
sarcomere of 0.025 nm/kPa at 10C (Fig. 5)). This increase
apparently is too small to affect Fmax or other parameters
of muscle fibers with this mutation beyond detection limit.
To directly test our findings, we have initiated single
molecule approaches to see whether the increase in cross-
bridge stiffness expected from our fiber studies can be veri-
fied, including the difference for force-generating versus
rigor cross-bridges. Such experiments will also allow to
test the estimates of cross-bridge stiffness in control fibers
(Table 3), both in rigor (ca. 0.29 pN/nm, 5C) and during
isometric contraction (ca. 0.28 pN/nm with 66% strongly
bound myosin heads, 10C). These values seem significantly
lower than those found in single molecule measurements e.g.,
by Lewalle et al. (53) for rabbitmyosin (2 pN/nm) or byLinari
et al. (51) in rabbit psoas muscle fibers (1.7 pN/nm).
This discrepancy, however, might be due largely to the
myosin isoform studied. For slow myosin of rat at 22C,
values for cross-bridge stiffness of 0.3 pN/nm have been
observed in single molecule experiments (54). This number
is very similar to the values found here for slow myosin in
human M. soleus.
We also calculated the contribution of the cross-bridges
(after subtraction of filament compliance) to total half-sarco-
mere compliance of control fibers (Table 1) that was 0.55 in
rigor (0.031 nm/kPa / 0.056 nm/kPa) and 0.67 in isometric
contraction (0.052 nm/kPa / 0.078 nm/kPa). Data in Table
2 yield similar ratios. These values seem high compared to
values in the literature for fast fibers from rabbit psoas that
indicate a contribution of cross-bridge compliance <0.3 in
rigor and<0.5 in isometric contraction (51). This most likely
is due to the significantly lower cross-bridge stiffness (i.e.,
higher cross-bridge compliance) observed for the slow
myosin isoform (this study and Capitanio et al. (54)) whereas
filament compliance of slow and fast muscle fibers is rather
similar (49).
As an additional estimate of the fraction of cross-bridges
strongly attached to actin during isometric contraction in
slow fibers of soleus muscle from control individuals we
calculated the ratio of cross-bridge stiffness per half-sarco-
mere in isometric contraction versus rigor conditions. This
yields a ratio of 0.625 0.16 (n¼ 9) (stiffness of force gener-
ating wild-type cross-bridges divided by 31.75 kPa/nm). Forthe data in Table 2 that were obtained under slightly different
conditions the ratio is 0.745 0.16 (n¼ 14). Both ratios indi-
cate a high fraction of cross-bridges strongly attached to
actin in isometrically contracting slow soleus muscle fibers.
These ratios, however, are very similar to previous data from
x-ray diffraction studies on rabbit psoasmuscle fibers at 5C.
On average a fraction of strongly attached cross-bridges in
isometric contraction of 0.66 was found (52).
Based on this fraction of strongly bound cross-bridges
during isometric steady-state contraction we can estimate
from the observed isometric force per cross-sectional area
the active force generated per strongly attached myosin
head (F*). If we again consider in a half-sarcomere of a skel-
etal muscle fiber ~111  103 myosin heads/mm2, then the
time averaged contribution of 66% of all heads would yield
a force per strongly bound myosin head in control fibers
(Table 1) of 1.49 pN at 10C ((108.9  1015 pN/m2)/
(0.66  111  1015 heads/m2)) and 1.92 pN/myosin head
at 20C (Table 3). Other groups, however, found much
smaller fractions of cross-bridges strongly attached to actin
in isometric contraction, like 0.30 (51). For such a small frac-
tion, force per myosin head would be >3.2 pN at 10C
and >4.2 pN at 20C. For rabbit psoas muscle fibers force
per attached myosin head was estimated to be ~4.2 pN at
9C and 6.6 pN at 19C (51). However, our data were ob-
tained with human soleus muscle fibers containing only the
slow myosin isoform that is thought to generate a lower force
per head compared to the fast myosin isoform e.g., in rabbit
psoas muscle (51). Over all, these estimates obviously very
much depend not only on the conditions of the experiments
(temperature, ionic strength, solution composition, etc.) and
the assumptions regarding the fraction cross-bridges strongly
attached to actin during isometric contraction as well as the
values for myosin heads in a half-sarcomere, but quite
importantly also depend on the type of myosin studied
(slow versus fast isoform).
More relevant to our study, however, is the question of
whether and how much active force generated per mutated
myosin is affected by the mutations. Compared to the control
fibers isometric force generated per cross-sectional area of
fibers with mutation R723G increased, on average, 1.23-fold
and 1.21-fold at 10C and 20C, respectively (Table 1).
Assuming that 66% of all myosin heads are strongly attached
to actin during isometric force generation, wild-type myosin
heads, on average, generate an active force of 1.49 pN at
10C and 1.92 pN at 20C. With 62% mutated myosin heads
in fibers with mutation R723G (14), force per myosin head
with mutation R723G (F*R723G) is 1.99 pN and 2.56 pN at
10Cand20C(Table 3). This is a 1.37- and1.34-fold increase
compared to wild-type myosin heads at 10C and 20C,
respectively. The same estimate for myosin heads with muta-
tionR719W (isometric force increase 1.59-fold or 1.49-fold at
10Cand20C, respectively; seeTable 2 and (10)) and consid-
ering that ~1/3 of the force increase is due to changes in cross-
bridge cycling kinetics yields 1.77 pN/myosin head andBiophysical Journal 97(3) 806–824
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20C, respectively (Table 3). This is a 1.79-fold and a 1.63-
fold increase at 10C and 20C, respectively.
Based on Eq. 2b (F* ¼ S*  y0*) the y0-value for indi-
vidual mutated and wild-type heads (10C) can be calculated
from stiffness and force per myosin head. For controls and
myosin heads with mutation R723G (Table 1), y0 is 5.32 nm
and 3.83 nm, respectively (Table 3). For wild-type myosin
heads and heads with mutation R719W (Table 2) y0 is
5.14 nm and 4.54 nm, respectively (Table 3). This indicates
that y0, i.e., the elastic distortion of myosin heads during
force generation, is reduced for the heads with both mutation
R719W and R723G.
Implications for HCM
With regard to development of HCM, it is quite striking that
both mutations found to significantly increase force and stiff-
ness of the individual myosin heads, R719W and R723G, are
associated with a highly malignant phenotype of HCM
(31,32). The patient with mutation R719W had a severe
hypertrophy and was resuscitated from sudden death fol-
lowed by cardioverter-defibrillator implantation (31). In
general, this mutation is associated with premature death.
Affected individuals bearing this mutation have a marked
reduction in life expectancy (31). The two patients with
R723G mutation suffered from a severe form of the disease
with ventricular tachycardia, subsequent cardioverter-defi-
brillator implantation, and sudden death in the family (32).
Additionally, they developed heart failure with wall thinning
and systolic dysfunction leading to heart transplantation. In
contrast, the two patients with I736T mutation presented
with moderate septal hypertrophy and electrocardiogram
abnormalities but no conduction disease although they
were diagnosed with HCM for >20 years (33). No sudden
death was reported in this family.
Previous work from our laboratory provided some hints
toward a mechanism that might account for development
of HCM and might be common to different HCM mutations
even if force generation is enhanced. Studying the effects of
three different mutations in the myosin head domain on
calcium-sensitivity of a large number of soleus muscle fibers
from HCM patients we observed a significant functional
variability from fiber to fiber (35). This variability was
such that e.g., at a fixed intermediate calcium-concentration
force generation of different fibers from one and the same
patient with the R723G mutation varied from as low as
30% of maximum isometric force to up to 80% of Fmax. In
myocardium, such functional variability among individual
muscle cells will cause severe imbalances in force generation
as in myocardium the contractile apparatus is only partially
Ca2þ-activated. Particularly, myocytes arranged in series
would be affected by such imbalances in force generation,
presumably leading to sarcomere and/or myocyte disarray
and finally cardiac dysfunction. The problem of imbalancesBiophysical Journal 97(3) 806–824of force generation might be particularly severe in the case of
the considerably larger forces generated by myosin heads
with mutations R719W and R723G.
Because forces per myosin head of the slow myosin iso-
form even with mutation R719W seem to be significantly
lower than those of fast myosin isoforms, stability and
tensile strength of actin filaments most likely are not rele-
vant factors in the development of HCM. Myocyte hyper-
trophy, however, despite enhanced generation of isometric
force could be triggered by the unusually large forces ex-
erted on strain sensitive structures e.g., proteins in the
Z-line or transmembrane receptors, thus activating specific
signaling pathways in cells with larger force generation
(55,56). Concerning the development of myocyte disarray,
we are currently investigating our hypothesis that functional
variability among individual cells of the myocardium lead to
imbalances of force generation and thus contribute to devel-
opment of HCM. Imbalances among different cells might
actually present a common mechanism for development of
HCM even for mutations in sarcomeric proteins other than
myosin.
It is worth emphasizing that our hypothesis concerning
manifestation ofHCM is based on our studies ofHCM-related
mutations inmuscle fibers fromHCMpatients, i.e., within the
natural b-MHC isoform (ventricular myosin isoform) and
within the intact contractile apparatus. The importance to
study effects of human HCM-related mutations in the human
protein isoformwas directly demonstrated recently by Lowey
and colleagues (57). They showed that effects of mutation
R403Q introduced into the mouse-a-MHC were not only
different in magnitude but even contrary to the effects of
thismutation inmouse-b-MHC. From this it can be concluded
that e.g., the discrepancy between enhanced function
observed in the mouse model of HCM mutation R403Q
versus depressed function found in myosin from HCM
patients most likely is due to the different isoforms of myosin
under investigation. Likewise, for myosin mutation R719W,
different effects have been observed in studies on muscle
fibers from patients than seen when the R719W mutation
was introduced into different myosin isoforms (10,58,59).
Therefore it is unlikely that studies on proteins or tissue other
than of human origin will be sufficient to identify primary
effects of a particular mutation on human b-cardiac myosin
or to clarify mechanisms of HCM-development.
CONCLUSIONS
Characterization of several parameters of muscle function re-
vealed that HCM mutations R719W and R723G both are
associated with a much larger stiffness and force generation
of the individual mutated myosin heads, resulting in reduced
elastic distortion of the mutated myosin heads during
isometric force generation. Most interestingly, the increase
in stiffness of myosin heads with converter mutation
R719W and R723G, respectively, indicates that the converter
Cross-Bridge Compliance in Converter 823region is an element of themyosin head that contributes major
compliance to the acto-myosin cross-bridge. Therefore, in
skeletal muscle myosin it is the converter and/or its interac-
tions with closely associated structures such as the essential
light chain that will primarily be elastically distorted when
force is generated. In addition, the different amino acids found
at equivalent positions in other class II myosins suggest that
resistance to elastic distortion may be quite different for
different myosins.
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